The potential complementary role of targeted alpha therapy in the management of metastatic melanoma

被引：2

作者：

Brown, Michael P. ^{[1
,2
,3
]}

Bezak, Eva ^{[4
,5
,6
]}

Allen, Barry J. ^{[7
]}

机构：

[1] SA Pathol & Univ S Australia, Ctr Canc Biol, Translat Oncol Lab, Adelaide, SA, Australia

[2] Univ Adelaide, Sch Med, Adelaide, SA, Australia

[3] Royal Adelaide Hosp, Canc Clin Trials Unit, Adelaide, SA, Australia

[4] Univ South Australia, Int Ctr Allied Hlth Evidence, Sansom Inst, Adelaide, SA, Australia

[5] Univ South Australia, Sansom Ins Hlth Res, Adelaide, SA, Australia

[6] Univ Adelaide, Sch Phys Sci, Adelaide, SA, Australia

[7] Univ Western Sydney, Fac Med, Liverpool, NSW, Australia

来源：

MELANOMA MANAGEMENT | 2015年 / 2卷 / 04期

关键词：

Bi-213 alpha emitter; complementary therapies; immunotherapy; intralesional; kinase; inhibitors; metastatic; melanoma; Phase I clinical trials; radioisotopes; systemic; targeted alpha therapy;

D O I：

10.2217/mmt.15.26

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Standard treatments for metastatic melanoma have recently extended survival although many patients still succumb. Targeted alpha therapy (TAT) is a new therapeutic approach in which a cancer-targeting vector is labeled with an alpha-emitting radioisotope. Alpha-particles have the shortest range and highest energy transfer, and produce localized, highdensity and lethal ionization damage to DNA. Thus, the targeted radiation can kill isolated cancer cells circulating in blood and lymphatic vessels, regress metastatic cancer cell clusters, and disrupt the vasculature of solid tumors. Preclinical and clinical studies of TAT for metastatic melanoma demonstrate its safety and anti-tumor activity. We recommend ways in which TAT can be used to treat small-volume disease sometimes in conjunction with cytoreductive anti-melanoma therapies.

引用

页码：353 / 366

页数：14

共 97 条

[11]

Behnke J, 1988, Br J Neurosurg, V2, P193, DOI 10.3109/02688698808992669

[12]

Brons S, 2001, PHYS MEDICA, V17, P217

[13] UNIQUE GLYCOPROTEIN-PROTEOGLYCAN COMPLEX DEFINED BY MONOCLONAL-ANTIBODY ON HUMAN-MELANOMA CELLS [J].

BUMOL, TF ;

REISFELD, RA .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (04) :1245-1249

[14]

Burg MA, 1998, J CELL PHYSIOL, V177, P299, DOI 10.1002/(SICI)1097-4652(199811)177:2<299::AID-JCP12>3.3.CO

[15]

2-0

[16] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[17] Dosimetry of 125I and 103Pd COMS eye plaques for intraocular tumors: Report of Task Group 129 by the AAPM and ABS [J].

Chiu-Tsao, Sou-Tung ;

Astrahan, Melvin A. ;

Finger, Paul T. ;

Followill, David S. ;

Meigooni, Ali S. ;

Melhus, Christopher S. ;

Mourtada, Firas ;

Napolitano, Mary E. ;

Nath, Ravinder ;

Rivard, Mark J. ;

Rogers, D. W. O. ;

Thomson, Rowan M. .

MEDICAL PHYSICS, 2012, 39 (10) :6161-6184

[18]

Collaborative Ocular Melanoma Grp, 2006, ARCH OPHTHALMOL-CHIC, V124, P1684

[19] Somatic activation of KIT in distinct subtypes of melanoma [J].

Curtin, John A. ;

Busam, Klaus ;

Pinkel, Daniel ;

Bastian, Boris C. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (26) :4340-4346

[20]

Dadachova E, 2011, TARGETED RADIONUCLID

← 1 2 3 4 5 6 7 8 9 10 →